108 results about "Virus Protein" patented technology

The invention provides a subunit vaccine composition for porcine epidemic diarrhea, porcine delta coronal and porcine rotavirus as well as a preparation method and application of the subunit vaccine composition, and is characterized in that the subunit vaccine composition comprises prokaryotically expressed swine erysipelas filamentous bacillus SpaA protein, viral subunit protein and pharmaceutically acceptable adjuvants; wherein the amino acid sequence of the prokaryotically expressed swine erysipelas filamentous bacillus SpaA protein is as shown in SEQ No.1, and the viral subunit protein is selected from one or more of porcine epidemic diarrhea virus S protein, porcine delta coronavirus S protein and porcine rotavirus VP8 protein. The vaccine composition disclosed by the invention has the advantages of strong immunogenicity, good safety, no immune interference, high neutralizing antibody titer and long antibody duration.

The present invention belongs to the field of biomedicine. Provided are an influenza nanoparticle vaccine, and a preparation method therefor and the use thereof. A fusion protein containing an influenza virus strain HA protein or a fragment thereof, an antigenic epitope of the influenza virus protein, and ferritin, as an antigen, can induce an immune response effect against an influenza virus, and a vaccine composed of the fusion protein and an MF59 adjuvant can induce a protection effect against viral challenge and have a good cross-protection effect.

The application discloses a method for creating a new strain of Carassius auratus gibelii with resistance to Cyprinid herpesvirus 2 (CyHV2) infection, and the method is characterized in that a gene editing technology is used to target knockout gsdf-a a gene and gsdf-b a gene, and an experimental animal infection model of a homozygous knockout strain of the gene obtained by the technology is established. gsdf Results of the experimental animal infection model show that gsdf the CyHV2 infection resistance of the CyHV2 gene knockout Carassius auratus gibelii is significantly enhanced, the histopathological damage of the Carassius auratus gibelii after being infected with the virus is reduced, the expression of a virus protein ORF47 in liver tissue of the Carassius auratus gibelii is reduced, and the transcription level of a virus gene orf46r is significantly reduced. The new strain of Carassius auratus gibelii created by the method can avoid exogenous gene pollution, and has the advantages that the CyHV2 infection resistance of the Carassius auratus gibelii is significantly enhanced.

The invention refers to the use of PAP-I, a plant ribosome inactivating protein (RIP), or a functional variant thereof for treatment of human papillomavirus (HPV) infection and preventing or treating diseases or conditions associated with HPV infection.

This invention discloses a polypeptide that specifically binds to the coronavirus S protein, its encoding gene, and its applications, belonging to the field of molecular biology. The polypeptide specifically binding to the coronavirus S protein provided by this invention contains the following amino acid sequence: HFVKTPARWAWG, obtained through screening using phage display technology. The polypeptide provided by this invention can specifically bind to the coronavirus S protein and specifically block the binding of the coronavirus S protein to ACE2, thereby inhibiting coronavirus infection and can be used to prepare anti-coronavirus drugs.

The invention relates to the technical field of molecular generation, and discloses a reverse design method using a molecular spectrum as a medium to be applied to virus protein drug molecules, which comprises the following steps: firstly, constructing a data set containing a molecular SMILES identifier and a corresponding molecular spectrum, and carrying out drug-likeness and false positive preliminary screening on compounds by adopting Lipinski five rules and a PAINS mode; then training a conditional diffusion model, and generating a target molecular spectrum by taking specific drug properties as conditions; the spectrum is mapped into a molecular SMILES structure through a Transform decoder, so that accurate conversion from the spectrum to the molecule is realized; finally, through conformation optimization and stability verification, candidate drug molecules meeting specific treatment requirements are output. The method effectively avoids the invalid structure problem caused by cross-dimension generation, significantly improves the synthesizability and patent medicine potential of generated molecules, and is suitable for efficient molecular design of antiviral drugs, inhibitors and the like.

Described herein is a method of treating, ameliorating, and / or preventing an influenza viral infection in a subject, and / or immunizing a subject against an influenza viral infection, which include parenterally administering to the subject a first composition including a first compound in an amount sufficient to elicit systemic T and / or B cell response(s) against a first influenza virus in the subject; and administering to the subject a second composition including a viral protein of a second influenza virus through an administration route comprising intranasal, inhalational, intratracheal, intrapulmonary, and intrabronchial, in an amount sufficient to result in establishment of tissue-resident T cell(s), tissue-resident B cell(s), mucosal IgA, and / or systemic IgG specific against the influenza viral infection in the subject. Also described are a kit for performing the method, as well as methods and kits for boosting existing immunity against influenza viral infections.

This application relates to methods for preparing viral proteins, such as influenza hemagglutinin proteins and / or influenza neuraminidase proteins, immunogenic compositions comprising the viral proteins thus obtained and vaccines comprising the same, as well as methods of using the same, in particular in the prevention and / or treatment of diseases or conditions caused by viruses, such as influenza viruses.

This application relates to methods for preparing viral proteins, such as influenza hemagglutinin proteins and / or influenza neuraminidase proteins, immunogenic compositions comprising the viral proteins thus obtained and vaccines comprising the same, as well as methods of using the same, in particular in the prevention and / or treatment of diseases or conditions caused by viruses, such as influenza viruses.

The invention discloses a Nipah virus F protein monoclonal antibody and application thereof, the antibody comprises an antibody 2D12 and an antibody 3B10, and the Nipah virus F protein monoclonal antibody is prepared from Nipah virus F protein immunogen. The specific anti-Nipah virus F protein monoclonal antibody pair is prepared and detected, the monoclonal antibody pair can be specifically combined with the Nipah virus F protein, is high in titer and good in affinity and has neutralizing activity, and meanwhile, the detection kit prepared on the basis of the antibody pair can effectively carry out Nipah virus detection; and technical support can be provided for treatment, epidemiological monitoring and diagnosis of Nipah virus infection.

The application discloses a binding antibody against SARS-CoV-2 virus N protein and application thereof. The amino acid sequence of the heavy chain variable region of the monoclonal antibody N2E5 protected by the application is shown in SEQ ID NO. 1 in the sequence listing, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO. 2 in the sequence listing; the amino acid sequence of the heavy chain variable region of the monoclonal antibody N2E5 is shown in SEQ ID NO. 5 in the sequence listing, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO. 6 in the sequence listing. The kinetic constants K D of N2E5 and N8C6 with the N protein are 1.42*10 ‑8 M and 1.31*10 ‑8 M respectively. The antibody has high affinity with the N protein of the novel coronavirus and can be widely used in a novel coronavirus antibody detection kit and clinical treatment.

Antimicrobial eyewear features frames infused with or coated with antimicrobial additives, thereby offering continuous protection by actively destroying and inhibiting the growth of bacteria, fungi, parasites, and some viruses. The lenses may also have an antibacterial coating that destroys and inhibits bacterial growth. In some examples, the lenses are treated with a specialized strengthening liquid, wherein the liquid contains nano components that release heavy metal ions capable of invading the cell walls of bacteria, leading to bacterial elimination, destroying DNA molecules and proteases within the bacterial cells, denature viral proteins, break DNA chains, and result in cell death. Additionally, the strengthening liquid reduces dehydrogenase activity and interacts with various protein groups within the cell, thereby reducing the activity of these groups and effectively inhibiting the growth of E. coli and other bacteria on the lens surface.

The invention relates to the technical field of spreading modes of human viruses, in particular to a virus spreading mode prediction model based on interaction of virus protein and human protein, a prediction model construction method and a prediction method. The method specifically comprises the following steps: S1, constructing a training data set of a virus transmission mode; s2, based on the data in the S1, obtaining a virus-human protein interaction prediction result, vectorizing the prediction result by using 0 / 1 coding, and constructing a virus-human protein interaction matrix; and S3, using a machine learning algorithm and a feature selection project to construct and train a virus propagation mode prediction model based on the interaction of the virus protein and the human protein. The method for predicting the virus propagation mode of interaction between the virus protein and the human protein is convenient to use and wide in application range; the method is especially suitable for new viruses or unknown viruses which are not fully researched, and can realize efficient and rapid propagation mode identification.

The application discloses a method for improving the resistance of citrus to Huangyanbing by using ClPsaN gene, comprising the following steps: (1) cloning a VIGS fragment of the citrus ClPsaN gene; (2) constructing two VIGS expression vectors of TRV and CLBV; and (3) transforming the VIGS expression vector into citrus to obtain VIGS plants in which the citrus ClPsaN gene is silenced. According to the method, the VIGS vector of the citrus ClPsaN gene is constructed, then the vector is transformed into citrus, and the obtained citrus plants can obviously show resistance to Huangyanbing. The titer of Huangyanbing, i.e., Huangyanbing yellow vein-illness virus, can be reduced by 22-34%, and the accumulation amount of virus protein can be reduced by 35-50%, so that the incidence of Huangyanbing is significantly reduced. In addition, the TRV silencing of the citrus ClPsaN gene does not affect the phenotype of the citrus plants, and the citrus ClPsaN gene can be used as a candidate gene to be used in the breeding of citrus plants resistant to Huangyanbing by using VIGS silencing, RNA interference and gene editing technologies in cooperation with multiple genes of the citrus plants resistant to or susceptible to Huangyanbing.

The present invention includes composition and methods for making multivalent vaccines for immunization against Flavivirus and / or arboviruses including a multivalent Virus Like Particles (VLP) and mixtures thereof, the method comprising: method of making a Flavivirus and / or arboviruses Virus Like Particles (VLP) comprising: inserting two or more nucleic acids that encode at least one Flavivirus protein into a lentiviral backbone vector; generating a lentivirus by transfecting a first cell line with the lentiviral backbone vector and isolating the lentivirus therefrom; transducing a second cell line with the lentivirus; culturing the transduced cell line under conditions in which the multivalent Flavivirus Virus Like Particles (VLP) are released from the cell line; and isolating the Flavivirus Virus Like Particles (VLP) from a culture supernatant, wherein a cell line makes a virus-specific VLP, and the VLPs are purified and then mixed in different combinations to make the multivalent vaccine.

The invention discloses application of alpha-terpilenol in preparation of a medicine for resisting respiratory syncytial virus infection, and relates to the technical field of respiratory syncytial virus prevention and treatment. The alpha-terpilenol can inhibit the virus titer of the RSV in vitro, and obviously inhibits the infection of the RSV on cells. The alpha-terpilenol can maintain the normal alveolar structure of a mouse in vivo, inhibit inflammatory response and inhibit the expression of virus F protein in the lung, so that the alpha-terpilenol has remarkable anti-respiratory syncytial virus activity in vivo and in vitro. According to the invention, a new treatment scheme is provided for respiratory syncytial virus infection, and the treatment cost of respiratory syncytial virus infection is reduced.

The invention provides viral vectors on the basis of adeno-associated virus (AAV) for transducing cells with a nucleic acid construct contained in the viral vector for delivery of a nucleic acid construct by the viral vector, which in their capsid proteins contain an insert arranged at an integration site for a peptide insert in viral proteins which integration site is located on a protruding loop of VP1, VP2 and / or VP3. The insert provides the viral vectors with specificity for targeting inner ear cells, especially for delivery of nucleic acid constructs contained in the viral vectors to inner ear cells.

The invention relates to the technical field of biology, in particular to an anti-EB (Epstein-Barr) virus Rta protein antibody as well as an antigen binding fragment and application thereof. The invention provides an antibody capable of specifically recognizing EB (Epstein-Barr) virus Rta protein or an antigen binding fragment thereof, the antibody or the antigen binding fragment thereof comprises complementary determining regions VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2 and VLCDR3, and the amino acid sequences of the complementary determining regions are respectively as follows: GFTFSSSYG, ISSSRYT, ARHLLSGTSSFDC, KSLHSNGNTY, YMS and MQSLEYPFT. The antibody or the antigen binding fragment thereof can be used as a positive control and a calibrator in a nasopharyngeal carcinoma in-vitro diagnostic kit, so that the problem of batch-to-batch difference existing in nasopharyngeal carcinoma positive serum is avoided, and the production cost of the nasopharyngeal carcinoma detection kit is reduced.

The application discloses a composite material sensor and a preparation method and application thereof, and belongs to the field of composite material sensors.The composite material sensor is composed of an immune substrate and an immune probe.The immune substrate is prepared by combining ZIF-67 and VP through an in-situ growth method, and is loaded with a novel coronavirus antibody and a BSA protective layer on the surface.The immune probe is loaded with RhB Raman molecules, a novel coronavirus antibody and a BSA protective layer on the surface of BP NPs as a carrier.The composite material sensor has the advantages of a large specific surface area, which is beneficial to the better combination of ZIF-67 on the surface and the formation of a heterojunction, and is beneficial to the capture and adsorption of target molecules and has a good chemical enhancement effect.The novel coronavirus can be detected through an immune reaction.The application has the advantages of simple operation and low cost, and can be applied to large-scale rapid detection of novel coronavirus proteins in human saliva, blood and water samples and the like.

The invention relates to a method for improving PCV2 recombinant baculovirus protein expression, and belongs to the technical field of recombinant virus protein preparation. In order to solve the problem of low expression quantity of the existing PCV2 recombinant virus protein, the invention provides a method for efficiently expressing the PCV2 recombinant virus protein, the method comprises the step of carrying out H5 cell suspension culture for preparation, and we find that when glucose is lower than 5g / L in the culture process, glucose is added to 5-8g / L, glutamine is supplemented to 3-5mM, and beta-mercaptoethanol is added to 0.01-0.1 mM, the expression quantity of the PCV2 recombinant virus protein is increased, and the expression quantity of the PCV2 recombinant virus protein is increased. The expression quantity of the target protein can be obviously increased, and the expression quantity reaches 240 g / L or above. The method is simple in process, condition parameters are easy to control, cell culture is extremely easy to amplify, and the effects of cell culture, virus passage and target protein expression can be achieved without changing liquid in the cell culture period after virus inoculation.

The invention discloses a reporting system for intracellular evaluation of nsp3 protein PLpro cleavage activity as well as related protein and coding gene thereof. The reporting system comprises cleavage-inducing protein for intracellular evaluation of nsp3 protein PLpro cleavage activity and a GFP (Green Fluorescent Protein) detection reagent. The cleavage-induced protein can form a GFP (Green Fluorescent Protein) report protein-nsp2 / 3 cleavage site-PLpro active protein or a PLpro active protein-nsp3 / 4 cleavage site-GFP report protein. The reporting system not only indicates the activity of the PLpro, but also indicates various factors which can influence membrane localization and protein interaction in the nsp2 / 3 or nsp3 / 4 cutting process of the new coronavirus protein nsp3, so that the reporting system has the characteristics of low background, multiple targets and the like, and can be used for intracellular screening of a PLpro inhibitor and an inhibitor targeting the nsp2 / 3 or nsp3 / 4 process.

The invention discloses an anti-African swine fever p72 protein single-chain antibody as well as a nucleic acid molecule, a recombinant expression vector, a preparation method and application thereof, and belongs to the technical field of detection of pathogenic microorganisms of livestock. The single-chain antibody is formed by sequentially connecting a heavy chain variable region, a connecting peptide and a light chain variable region, and the amino acid sequence of the single-chain antibody is shown as SEQ ID NO: 1. The invention also provides a nucleic acid molecule for coding the single-chain antibody as well as a recombinant expression vector and a host cell of the nucleic acid molecule. The single-chain antibody with high affinity and high specificity is obtained by screening through a phage display technology, is only combined with the African swine fever virus p72 protein, does not react with common swine virus protein, is small in molecular weight and good in stability, is suitable for various detection scenes such as immunodetection and histochemical analysis, and has good application prospects. The kit can be used for developing products such as a rapid diagnostic kit and a lateral flow test strip, and is suitable for detecting African swine fever.

Provided are an influenza vaccine as a nasal spray, and a preparation method therefor and the use thereof. In the vaccine, a fusion protein contains an influenza virus strain HA protein or a fragment thereof, an influenza virus protein epitope and ferritin; and an adjuvant is a CpG1009 adjuvant for enhancing humoral immunity and cellular immunity. The vaccine composed of the fusion protein and the new CpG adjuvant can induce a strong protective effect against challenge.

Provided are a fusion protein, and a nucleic acid molecule comprising a nucleotide sequence encoding the fusion protein. The present invention also relates to a vaccine comprising the fusion protein or the nucleic acid molecule. Furthermore, the present invention also relates to a method for preventing and / or treating RSV infections or diseases and / or symptoms caused by RSV infections by means of using the fusion protein, nucleic acid molecule and vaccine.

This invention belongs to the field of aquaculture technology and relates to a novel use of capsaicin, particularly its use in the preparation of drugs and / or feed additives for the prevention and treatment of fish viral infections. The core of this invention lies in the significant protective effect of capsaicin against carp spring viremia virus (SVCV), grass carp reovirus (GCRV), and carp herpesvirus type 2 (CyHV-2) infections, effectively inhibiting the transcription of SVCV, GCRV, and CyHV-2 viral genes and the expression of viral proteins. Feed additives and / or drugs containing capsaicin can be used for the prevention and treatment of fish viral diseases, offering advantages such as high protective efficiency and environmental friendliness.

The invention relates to the technical field of protein detection, and particularly provides a double-antibody sandwich ELISA kit for detecting H5 subtype avian influenza virus M1 protein. The inactivated H5 subtype avian influenza virus subjected to sucrose density gradient centrifugal concentration and purification is used as an immunogen to immunize a BALB / c mouse, the H5 subtype avian influenza virus M1 protein is used for screening to obtain a detection antibody, and the detection antibody is prepared after an SPF chicken is immunized. On the basis, a double-antibody sandwich ELISA kit for detecting the H5 subtype avian influenza virus M1 protein is researched and developed. The technology can be used for quantitative detection of H5 subtype avian influenza M1 protein and quality control of avian influenza subunit products, and ensures stable product quality; and the method can also be used for detecting the expression characteristics of the recombinant avian influenza baculovirus seed protein.

The invention relates to a recombinant chimeric antigen aiming at bovine nodular skin disease virus as well as a preparation method and application of the recombinant chimeric antigen. The bovine nodular skin disease virus recombinant chimeric antigen comprises four immunogens which are connected in series and fused according to a specific sequence: bovine nodular skin disease virus ORF122, ORF060, ORF074 and ORF117 proteins or antigenic fragments thereof, and can excite immune response aiming at two infectious virus particles, namely, intracellular mature virus particles (IMV) and extracellular membrane virus particles (EEV); therefore, the specific immune protection effect on the bovine nodular skin disease virus is efficiently excited; in addition, the bovine nodular skin disease virus vaccine disclosed by the invention also has good safety, quick responsiveness and productivity support, and has an extremely good clinical application prospect.

The invention discloses a monoclonal antibody LayG-1069 of a Langya virus G protein as well as preparation and application of the monoclonal antibody LayG-1069. The monoclonal antibody LayG-1069 for the Langya virus G protein, which is obtained by screening, is high in binding capacity with the LayV G protein, and is relatively high in cross reactivity with the MojV G protein. The application of the monoclonal antibody LayG-1069 in various biological methods is verified through the embodiment of the invention, and the monoclonal antibody LayG-1069 has ADCC and ADCP activities. The monoclonal antibody LayG-1069 is expected to become a detection antibody for LayV and MojV infection, and has the potential of becoming a candidate drug for treating LayV and MojV infection.

The invention relates to an immunogenic formulation that confers protection against respiratory viruses which comprises an attenuated recombinant strain of Bacillus Calmette and Guerin (BCG), in a concentration of between 104 109 bacteria, which expresses at least one immunogenic protein or fragment of the respiratory syncytial virus (RSV). And to the use of this immunogenic formulation to prepare a vaccine to prevent, treat, or attenuate infections of respiratory viruses, especially hRSV and / or hMPV.